HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Pediatric Supplement Hearing Planned In House; Durbin Slams DSHEA

This article was originally published in The Tan Sheet

Executive Summary

The House Energy & Commerce/Oversight & Investigations subcommittee is planning a hearing on dietary supplements for obesity in children June 16

You may also be interested in...

Trade Group Efforts, Timing Bring AER System Concerns To Fore

Congressional and industry cooperation over a broad dietary supplement/OTC drug adverse event reporting system is the result of long-term lobbying combined with recent momentum spurred by widespread safety concerns

PediaLean Letter Signals Widening Commerce Cmte. Supplement Probe

The House Energy & Commerce Committee has expanded its investigation of the dietary supplement industry with a letter to the manufacturer of the PediaLean pediatric weight-loss supplement

Supplements Containing Stimulants Would Need Preapproval Under Durbin Bill

Sen. Charles Schumer (D-N.Y.) is expected to co-sponsor the "Dietary Supplement Safety Act" (S 722), which was introduced March 26 by Sen. Richard Durbin (D-Ill.)





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts